Wegovy: Semaglutide Reduces Migraine Severity, Especially in Women

A study has found that treatment with semaglutide led to reduced triptan usage in women. However, no significant effect was observed in men with overweight or obesity. Experts say reductions in inflammation or intracranial pressure could play a role.

Sex-related differences in how the body handles semaglutide also appear to be important. More research is needed before semaglutide can be recommended as a migraine treatment. A recent nationwide study in Denmark has revealed that women who start using semaglutide, a popular medication prescribed for weight loss, may experience a decrease in the need for standard migraine treatments. The researchers found that females using semaglutide had a noticeable reduction in their use of a class of drugs called triptans . The study has not yet been published in a peer-reviewed scientific journal, but was presented at the European Congress on Obesity (ECO2026) from May 12–15. The findings add to a growing interest in the potential benefits of semaglutide for migraine. Another recent study found that GLP-1 medications like semaglutide may help reduce migraine severity . Researchers from the University of Southern Denmark collaborated with Novo Nordisk, the pharmaceutical company behind semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes control), to analyze data from Danish health registries. These registers contain comprehensive health information on the entire population, enabling a detailed examination of medication use patterns. The study focused on adults who began semaglutide treatment for weight management between December 1, 2022, and June 30, 2024. It included nearly 150,000 people who started semaglutide during the study period, of whom about two-thirds were females. For each individual, the researchers tracked their use of triptans — the drugs commonly taken for acute migraine relief — for two years before starting semaglutide and for one year afterward.

Key points

• Sex-related differences in how the body handles semaglutide also appear to be important.
• More research is needed before semaglutide can be recommended as a migraine treatment.
• A recent nationwide study in Denmark has revealed that women who start using semaglutide, a popular medication prescribed for weight loss, may experience a decrease in the need for standard migrain…
• The researchers found that females using semaglutide had a noticeable reduction in their use of a class of drugs called triptans .
• The study has not yet been published in a peer-reviewed scientific journal, but was presented at the European Congress on Obesity (ECO2026) from May 12–15.